The CA Profile© includes the following tests:
HCG (Human chorianic gonadotropin) intact (IRMA) and intact plus, HCG beta, core, and its fragments (IMM) are normally made by the embryonic origin trophoblast cells. However, It may be present in most, if not all, types of cancer. These two procedurally totally different methods are being used to ascertain the validity of the often very low amount of the hormone in the blood. The IRMA is immunoradiometric assay, and the IMM is chemiluminescence. The tests will detect extremely low levels of the hormone, and are specific for it 98-99%. The IRMA test will measure down to 0.3 mIU/mL, and IMM to 0.2 mIU/mL. Dr.Schandl named this tumor marker "the pregnancy and/or malignancy hormone." HCG suppresses the immune system, starts and enhances DNA, RNA of protein synthesis, and generally it is produced under anaerobic cellular conditions by the trophoblast.
The HCG Urine test was studied and introduced at American Metabolic Laboratories. This test is now included in our Cancer Profile. It must be noted that American Metabolic Laboratories' Urine-HCG Test may be the one and only one of its kind for being quantitative down to less than 1.1 mIU/mL detection level. This test, unlike Doctor Navarro's for instance, requires about 0.5 mL of urine without any treatment, in its natural form. It is totally specific for the HCG hormone even in minute quantities. The old method requires acetone denaturation and extraction that yields a conglomerate of HCG, LH, FSH, and TSH hormones. All of the four structurally very similar hormones are precipitated by the harsh treatment and will add on to the reported HCG value. Postmenopausal women and older men with high LH and/or FSH, and hypothyroid individuals with high TSH may yield elevated "HCG" values. However, this hormone species is actually HCG-like (HCG-L) with one-half biological activity when compared to pregnancy or tumor generated HCG.
PHI enzyme channels cells into anaerobic metabolism, i.e. fermentation. This kind of cellular survival is what cancer cells favor. The more energy generating metabolic pathway is oxidative phosphorilation. This is the pathway normal cells require in the presence of oxygen. Hence, more oxygen is less cancer, and less oxygen is more cancer. PHI is called the autocrine motility factor, i.e. malignancy or cancer spread factor. This means it is one of the major causes of metastatic spread.
CEA is a broad spectrum cancer marker. It is the carcinoembryonic antigen. It can be elevated in all sorts of cancers. It is very prevalent in cancers of the breast, colon, and rectum. Like all the others, it is an independent cancer marker that by itself may be sufficient as a diagnostic adjunct.
GGTP is the most sensitive test for the liver, however, it may be elevated in diseases of the heart, lungs, and kidneys. It is not a tumor marker however, it may be elevated in cancer patients as a result of either cancer spread or toxic therapy.
TSH or thyroid stimulating hormone regulates basic metabolic rate, i.e. oxygen utilization. A high level, i.e. hypothyroidism, may be a prelude to cancer. Chemotherapy frequently causes this anaerobic condition by injuring the thyroid gland.
DHEA-S is the "adrenal anti stress, pro immunity, longevity hormone", according to Dr. Schandl. The immune system is impaired without adequate amounts of this hormone. Most, if not all cancer patients and those in the process of developing cancer have very low or no DHEA in their blood.
This ultra sensitive method measures low or high thyroid activity
||May be elevated in cancer, stress-related to cancer, a developing cancer, or pregnancy. It will detect only intact hormone. It may not detect HCG-L
||Normal: Less than 1 mIU/mL; gray zone: up to 3.0 mIU/mL
||May be elevated in cancer, stress-related to cancer, a developing cancer, or pregnancy.
It measures intact and all other molecular forms of the hormone, including HCGL-S (HCG-like)
||Normal: Less than 1mIU/mL; gray zone: up to 3.0 mIU/mL
||May be elevated in cancer, stress-related to cancer, a developing cancer, pregnancy, or the presence of HCG like substance (HCGL)
||Normal: 0.0 - 1.0; gray zone 1.1 - 3.8 mIU/mL
||Elevations may warn of a developing cancer; cancer; active AIDS, acute viral disease, acute heart, liver, or muscle disease
||Normal: Less than 34 U/L; gray zone: up to 40.00 U/L
||Diseases of the liver, pancreas, and the biliary system. Also heart, lung, kidney ailments
||Normal: Females less than 29 IU/L, Males less than 35 IU/L
||Thyroid stimulating hormone, for thyroid and oxygen metabolism.
||Normal: 0.4 - 4.0 mcIU/mL
||Adrenal anti-stress, immunity, and longevity hormone; low or zero in most cancer patients
||Normal: Females 35 - 430 mcg/dL, Males 80-560 mcg/dL. Results must be interpreted in reference to a person's age
||Carcinoembryonic antigen may be elevated in any malignancy
||Normal: Less than 3.0 ng/mL; gray zone is 3.1 - 5.0 ng/mL
*** Laboratory studies indicated that urinary HCG -IRMA was negative in 99% of the tested subjects. This means that very little, if any, tumor generated HCG was filtered out. The urine should be tested by the IMM method, however, because tumor originated ß and fragments can be present that the IRMA method excludes.